Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Masunari

CONSOLIDATION THERAPY USING 90 Y-Ibritumomab TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB FOR RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRiZ2012)

Hematological Oncology

English

Related publications

Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma

British Journal of Haematology

Hematology

2018

English

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (With Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2017

English

Consolidation Therapy for Follicular Lymphoma

European Oncology and Haematology

Oncology

Hematology

2008

English

Bendamustine and Rituximab in Elderly Patients With Low-Tumour Burden Follicular Lymphoma. Results of the LYSA Phase II BRIEF Study

British Journal of Haematology

Hematology

2018

English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma

English

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Journal of Clinical Oncology

English

P53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan

International Journal of Radiation Oncology Biology Physics

English

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Hematological Oncology

English

90 Y-Ibritumomab Tiuxetan in Patients With Extra-Nodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (Malt Lymphoma) - The Zeno Study

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Masunari

CONSOLIDATION THERAPY USING 90 Y-Ibritumomab TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB FOR RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRiZ2012)

Related publications

Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (With Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

Consolidation Therapy for Follicular Lymphoma

Bendamustine and Rituximab in Elderly Patients With Low-Tumour Burden Follicular Lymphoma. Results of the LYSA Phase II BRIEF Study

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

P53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

90 Y-Ibritumomab Tiuxetan in Patients With Extra-Nodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (Malt Lymphoma) - The Zeno Study